| Thursday, November 1,
2007 |
| 8:00 AM–8:15 AM |
Welcome/SARC Update |
Laurence Baker |
| 8:15 AM–9:00 AM |
Chawla/Rosenfeld Developmental Therapeutics Symposium |
Lee Helman |
| 9:00 AM–10:15 AM |
Review of Ongoing SARC Trials |
|
| |
SARC 003 Gemcitabine/Docetaxel in Bone Sarcoma |
Beth Fox |
| |
SARC 004 Neoadjuvant Imatinib in DFSP |
Scott Schuetze |
| |
SARC 005 Adjuvant Therapy High Risk Uterine Leiomyosarcoma |
Martee Hensley |
| |
SARC 006 MPNST: Sporatic versus NF1 associated |
Brigitte Widemann |
| |
SARC 007 Perifosine in chemoinsensitive sarcoma |
(TBD) |
| |
SARC 009 Dasatinib in metastatic sarcoma |
Scott Schuetze |
| |
Review of Pending Trials |
|
| |
SARC 010 Dasatinib in GIST |
Jon Trent |
| |
SARC 011 IGF-1R in selected sarcomas |
Alberto Pappo |
| |
SARC 012 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung |
(TBD) |
| |
Prioritizing SARC Studies |
Laurence Baker |
| 10:15 AM–10:30 AM |
Break |
|
| 10:30 AM–12:00
PM |
Closed Session (Limited to attendees who have signed CDA with SARC) |
|
